Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study

Michael Frass, Peter Lechleitner, Christa Gründling, Claudia Pirker, Erwin Grasmuk-Siegl, Julian Domayer, Maximilian Hochmair, Katharina Gaertner, Cornelia Duscheck, Ilse Muchitsch, Christine Marosi, Michael Schumacher, Sabine Zöchbauer-Müller, Raj K Manchanda, Andrea Schrott, Otto Burghuber, Michael Frass, Peter Lechleitner, Christa Gründling, Claudia Pirker, Erwin Grasmuk-Siegl, Julian Domayer, Maximilian Hochmair, Katharina Gaertner, Cornelia Duscheck, Ilse Muchitsch, Christine Marosi, Michael Schumacher, Sabine Zöchbauer-Müller, Raj K Manchanda, Andrea Schrott, Otto Burghuber

Abstract

Lessons learned: Conventional medicine and homeopathy work well together. Quality of life improves with additive homeopathy in patients with non-small cell lung cancer (NSCLC). Survival improves with additive homeopathy in patients with NSCLC.

Background: Patients with advanced non-small cell lung cancer (NSCLC) have limited treatment options. Alongside conventional anticancer treatment, additive homeopathy might help to alleviate side effects of conventional therapy. The aim of the present study was to investigate whether additive homeopathy might influence quality of life (QoL) and survival in patients with NSCLC.

Methods: In this prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter, phase III study, we evaluated the possible effects of additive homeopathic treatment compared with placebo in patients with stage IV NSCLC, with respect to QoL in the two randomized groups and survival time in all three groups. Treated patients visited the outpatients' centers every 9 weeks: 150 patients with stage IV NSCLC were included in the study; 98 received either individualized homeopathic remedies (n = 51) or placebo (n = 47) in a double-blinded fashion; and 52 control patients without any homeopathic treatment were observed for survival only. The constituents of the different homeopathic remedies were mainly of plant, mineral, or animal origin. The remedies were manufactured by stepwise dilution and succussion, thereby preparing stable Good Manufacturing Practice grade formulations.

Results: QoL as well as functional and symptom scales showed significant improvement in the homeopathy group when compared with placebo after 9 and 18 weeks of homeopathic treatment (p < .001). Median survival time was significantly longer in the homeopathy group (435 days) versus placebo (257 days; p = .010) as well as versus control (228 days; p < .001). Survival rate in the homeopathy group differed significantly from placebo (p = .020) and from control (p < .001).

Conclusion: QoL improved significantly in the homeopathy group compared with placebo. In addition, survival was significantly longer in the homeopathy group versus placebo and control. A higher QoL might have contributed to the prolonged survival. The study suggests that homeopathy positively influences not only QoL but also survival. Further studies including other tumor entities are warranted.

Trial registration: ClinicalTrials.gov NCT01509612.

Keywords: Additive homeopathy; Adult oncology; Complementary and alternative medicine; Global health status; Lung cancer; Survival.

© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Figures

Figure 1
Figure 1
Kaplan‐Meier estimates of overall survival time in the three groups. Crosses indicate time points of censoring (i.e., no patients died after this time point in this study group). Bold italicized values are statistically significant.
Figure 2
Figure 2
Study protocol.Abbreviations: BL, baseline; verum, homeopathy; wks, weeks.
Figure 3
Figure 3
CONSORT diagram.

References

    1. Cancer facts and statistics. American Cancer Society Web site. 2016. . Accessed February 22, 2017.
    1. Jemal A, Siegel R, Xu J et al. Cancer statistics. CA Cancer J Clin 2010;60:277–300.
    1. Molina JR, Yang P, Cassivi SD et al. Non‐small cell lung cancer: Epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584–594.
    1. Hirsch FR, Scagliotti GV, Mulshine JL et al. Lung cancer: Current therapies and new targeted treatments. Lancet 2017;389:299–311.
    1. Ettinger DS, Wood DE, Aisner DL et al. Non‐small cell lung cancer, version 2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2017;15:504–535.
    1. Shojaee S, Nana‐Sinkam P. Recent advances in the management of non‐small cell lung cancer. F1000Res 2017;6:2110.
    1. Tanaka K, Akechi T, Okuyama T et al. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 2002;23:417–423.
    1. Iyer S, Taylor‐Stokes G, Roughley A. Symptom burden and quality of life in advanced non‐small cell lung cancer patients in France and Germany. Lung Cancer 2013;81:288–293.
    1. Iyer S, Roughley A, Rider A et al. The symptom burden of non‐small cell lung cancer in the USA: A real‐world cross‐sectional study. Support Care Cancer 2014;22:181–187.
    1. Temel JS, Pirl WF, Lynch TJ. Comprehensive symptom management in patients with advanced‐stage non‐small‐cell lung cancer. Clin Lung Cancer 2006;7:241–249.
    1. Cooley ME. Symptoms in adults with lung cancer. A systematic research review. J Pain Symptom Manag 2000;19:137–153.
    1. Akin S, Can G, Aydiner A et al. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs 2010;14:400–409.
    1. Cella D, Peterman A, Hudgens S et al. Measuring the side effects of taxane therapy in oncology: The functional assessment of cancer therapy‐taxane (FACT‐taxane). Cancer 2003;98:822–831.
    1. Sloan JA, Zhao X, Novotny PJ et al. Relationship between deficits in overall quality of life and non‐small‐cell lung cancer survival. J Clin Oncol 2012;30;1498–1504.
    1. Wang XS, Shi Q, Lu C et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced non‐small cell lung cancer. Cancer 2010;116:137–145.
    1. Daly BJ, Douglas SL, Foley H. Psychosocial registry for persons with cancer: A method of facilitating quality of life and symptom research. Psychooncology 2007;16:358–364.
    1. Hahnemann S. Organon of Medicine. 6th ed. New Delhi, India: B. Jain Publishers Ltd., 1994.
    1. Kent JT. Lectures on Homoeopathic Philosophy. New Delhi, India: B. Jain Publishers Ltd., 1993; 92–93.
    1. Frass M, Friehs H, Thallinger C et al. Influence of adjunctive classical homeopathy on global health status and subjective wellbeing in cancer patients ‐ A pragmatic randomized controlled trial. Complement Ther Med 2015;23:309–317.
    1. Gleiss A, Frass M, Gaertner K. Re‐analysis of survival data of cancer patients utilizing additive homeopathy. Complement Ther Med 2016;27:65–67.
    1. Brien S, Lachance L, Prescott P et al. Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: A randomized controlled clinical trial. Rheumatology (Oxford) 2011;50:1070–1082.
    1. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer. J Clin Oncol 2008;26:3543–3551.
    1. Muchitsch I. Remedy production and quality, Potentisation. In: Frass M, Bündner M, eds. Homeopathy in Intensive and Emergency Medicine. Kandern, Germany: Narayana Verlag, 2015: 37–55.
    1. Fayers P, Bottomley A; EORTC Quality of Life Group; Quality of Life Unit. Quality of life research within the EORTC‐the EORTC QLQ‐C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38(suppl 4):25–133.
    1. Hays RD, Sherbourne CD, Mazel RM. The RAND 36‐item health survey 1.0. Health Econ 1993;2:17–227.
    1. Pirker R, Pereira JR, Szczesna A et al.; FLEX Study Team . Cetuximab plus chemotherapy in patients with advanced non‐small‐cell lung cancer (FLEX): An open‐label randomised phase III trial. Lancet 2009;373:1525–1531.
    1. Kawase A, Yoshida J, Ishii G et al. Differences between squamous cell carcinoma and adenocarcinoma of the lung: Are adenocarcinoma and squamous cell carcinoma prognostically equal? Jpn J Clin Oncol 2012;42:189–195.
    1. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non‐small‐cell lung cancer. N Engl J Med 2010;363:733–742.
    1. Deng GE, Rausch SM, Jones LW et al. Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence‐based clinical practice guidelines. Chest 2013;143(suppl 5):e420S–e436S.
    1. Frass M, Dielacher C, Linkesch M et al. Influence of potassium dichromate on tracheal secretions in critically ill patients. Chest 2005;127:936–941.
    1. Gandhi L, Rodríguez‐Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med 2018;378:2078–2092.
    1. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009;7:102.
    1. Lu W, Giobbie‐Hurder A, Freedman RA et al. Acupuncture for chemotherapy‐induced peripheral neuropathy in breast cancer survivors: A randomized controlled pilot trial. The Oncologist 2020;25:310–318.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir